Stifel Downgrades Tokai Pharmaceuticals (TKAI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Wall St set for best week since April as payrolls surprise eases rate-hike jitters
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Oil gains on US jobs report, worries over peace talks
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:44 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $2.00.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreBMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:43 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $1.70 (from $11.00) following the discontinuation of ARMOR3-SV.
Analyst Do Kim commented, "We are downgrading Tokai (TKAI) shares to Market Perform from Outperform, following the... More
Pre-Open Stock Movers 07/26: (EXAS) (CRY) (NFLX) Higher; (TKAI) (CRME) (MSTX) (NDLS) (MBLY) Lower (more...)
July 26, 2016 9:32 AM EDTToday's Pre-Open Stock Movers
Tokai Pharmaceuticals Inc. (Nasdaq: TKAI) 69% LOWER; announced that it plans to discontinue the ARMOR3-SV clinical trial, the companys pivotal Phase 3 study comparing galeterone to enzalutamide in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients whose prostate tumors express AR-V7, following the recommendation made yesterday by the trials independent Data Monitoring... More
Janney Montgomery Scott Downgrades Tokai Pharmaceuticals (TKAI) to Neutral
July 26, 2016 8:50 AM EDTJanney Montgomery Scott downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Buy to Neutral with a price target of $2.00 (from $12.00).
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreWells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 8:23 AM EDTWells Fargo downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreTokai Pharma (TKAI) will resume trading at 7:30am ET
July 26, 2016 7:20 AM EDTTokai Pharma (NASDAQ: TKAI) will resume trading at 7:30am EDT.
... MoreTokai Pharma (TKAI) to Cease ARMOR3-SV Clinical Trial
July 26, 2016 7:05 AM EDTTokai Pharmaceuticals Inc. (Nasdaq: TKAI) announced that it plans to discontinue the ARMOR3-SV clinical trial, the companys pivotal Phase 3 study comparing galeterone to enzalutamide in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients whose prostate tumors express AR-V7, following the recommendation made yesterday by the trials independent Data Monitoring Committee (DMC).
Based on a review of all safety and efficacy data, the DMC determined that the ARMOR3-SV trial will likely not succeed in meeting its primary endpoint of demonstrating an improvement in radiographic progression-free survival (rPFS) for galeterone... More
Tokai Pharma (TKAI) trading halted with news pending
July 26, 2016 6:55 AM EDTTokai Pharma (NASDAQ: TKAI) trading halted with news pending.
... More